Abstract
Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 444-446 |
| Number of pages | 3 |
| Journal | Gynecologic Oncology |
| Volume | 75 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Oncology
Cite this
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer : A gynecologic oncology group trial. / Markman, Maurie; Blessing, John A.; De Geest, Koenraad; Morgan, Mark; Look, Katherine Y.; Herzog, Thomas J.; Rose, Peter G.
In: Gynecologic Oncology, Vol. 75, No. 3, 12.1999, p. 444-446.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer
T2 - A gynecologic oncology group trial
AU - Markman, Maurie
AU - Blessing, John A.
AU - De Geest, Koenraad
AU - Morgan, Mark
AU - Look, Katherine Y.
AU - Herzog, Thomas J.
AU - Rose, Peter G.
PY - 1999/12
Y1 - 1999/12
N2 - Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.
AB - Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=0032763429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032763429&partnerID=8YFLogxK
U2 - 10.1006/gyno.1999.5640
DO - 10.1006/gyno.1999.5640
M3 - Article
C2 - 10600304
AN - SCOPUS:0032763429
VL - 75
SP - 444
EP - 446
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 3
ER -